SAMIA is an advanced clinical decision support system (CDSS) for Mast Cell Activation Syndrome. Based on artificial intelligence, it offers a structured assessment guide, grounded in the most up-to-date scientific evidence.
Developed with passion by bluemedtech.AI
Project sponsored by Alfasigma Iberia.
SAMIA provides a clinical chatbot designed to assist you with the SAM classification. This AI agent is trained and adjusted periodically to improve the accuracy and clarity of its responses, always functioning as a support tool and never as a substitute for professional clinical judgment.
Sponsored subscriptionThe SAMIA agent works with the same intuitive logic as the diagnostic algorithm, so you can integrate it into your clinical practice with no learning curve. Browse the sections, ask your questions and get step-by-step support in seconds.
Log inA curated collection of key articles and documents about the disease, selected and continuously reviewed by our medical team.
Have a look